---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274137"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:47:26.624625+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines completes acquisition of EQRx; exchange ratio 0.1112

## Summary
- Acquisition closed Nov 9, 2023; EQRx stockholders received 0.1112 shares of RVMD common per EQRx share.
- EQRx common stock and warrants delisted from Nasdaq; EQRx ceases as separate public company.
- Sandra J. Horning appointed to RVMD board as EQRx designee, effective upon closing.
- Share issuance proposal approved by ~90% of votes cast at special meeting.

## SEC filing metadata
- accession: 0001193125-23-274137
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/d287738d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274137
- JSON: https://secwatch.observer/filing/0001193125-23-274137.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274137.txt

## Key facts
- Executive change
  Sandra J. Horning was appointed as Director at Revolution Medicines, Inc..
  - Action: appointed
  - Role: Director
  source text: the Revolution Medicines board of directors (the “Board”) appointed Sandra J. Horning, M.D., as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm
- M&A Transactions
  Revolution Medicines, Inc. completed an acquisition involving EQRx, Inc. (closed 2023-11-09).
  - Action: acquisition
  - Counterparty: EQRx, Inc.
  - Closing: 2023-11-09
  source text: On November 9, 2023, Revolution Medicines, Inc., a Delaware corporation (“Revolution Medicines”), completed the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm
- Shareholder Votes
  Revolution Medicines, Inc. shareholders approved Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the "Share Issuance Proposal") at the 2023-11-08 meeting.
  - Proposal: merger approval
  - Outcome: passed
  - Meeting: 2023-11-08
  source text: Proposal No. 1: Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the “Share Issuance Proposal”). The Share Issuance Proposal was approved by the requisite vote of Revolution Medicines’ stockholders. Votes For Votes Against Abstentions Broker Non-Votes 85,738,003 9,442,157 123,934 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.